Guggenheim has identified Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) as its top pick within biotech, anchoring its recommendation on the company’s progress in late-stage clinical development for retinal disorders and the commercial opportunity for its lead candidate, Duravyu.
The investment bank set a $68 price target for Eyepoint on the basis of a sum-of-the-parts net-present-value framework. That valuation incorporates the probability-adjusted NPV for Duravyu in retinal indications and factors in Eyepoint’s expected cash position at the end of 2025.
Recent corporate updates underpin the timing in Guggenheim’s analysis. Eyepoint reported a second-quarter 2026 update confirming that topline results from the Phase III LUGANO study remain on track for August 2026. Separately, the company has formally guided the LUCIA study readout to the fourth quarter of 2026; LUCIA had been expected approximately two months after LUGANO but is now explicitly scheduled later in the year.
The LUGANO topline is slated for an initial scientific disclosure at the Retina Society meeting in September, which Guggenheim notes will be the first venue for presenting LUGANO data to the retinal community. The timing of LUCIA positions Eyepoint to file a New Drug Application following that readout, subject to trial outcomes and regulatory considerations.
On efficacy expectations, Guggenheim anticipates that LUGANO will meet its non-inferiority primary endpoint and will demonstrate a clinically meaningful reduction in treatment burden. The firm points to investor attention shifting toward the supplement-free rate measured at the blended Week 52/56 primary endpoint. In Guggenheim’s view, a supplement-free rate near 50 percent—combined with 60 to 70 percent or more of patients in the zero-to-one rescue bucket—would be sufficient to support a durable, premium commercial launch for Duravyu.
Guggenheim’s choice reflects a valuation approach that slices the company into components after Eyepoint’s transition from a commercial-stage to a clinical-stage enterprise, a methodology consistent with how the firm covers similar companies in its universe.
The company has also drawn favorable analyst attention elsewhere: Stifel initiated coverage with a buy rating and Mizuho raised its price target to $39. Additionally, an independent safety committee completed a review of the Phase 3 trials for DURAVYU and recommended continuation of the trials without modification following a favorable safety assessment.
These developments form the core of Guggenheim’s constructive stance. The firm’s outlook depends on the upcoming clinical readouts, the supplement-free rate at the primary endpoint, and the company’s balance sheet as of year-end 2025.
Contextual note: The matters described above are based on company-provided updates and Guggenheim’s published valuation and expectations. Prospective investors should consider the timing and outcome risk associated with clinical trials and regulatory review when evaluating the company.